Product image of Igantibe (Human Hepatitis B Immunoglobulin) supplied by GNH India

Igantibe

Active Ingredient:
Human Hepatitis B Immunoglobulin
Origin:
EU

Igantibe (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Igantibe, is an immunoglobulin presented as a unspecified strength and dosage form for intramuscular use. It provides passive immunity to individuals at risk of hepatitis B virus infection, including post‑exposure prophylaxis and newborns of HBsAg‑positive mothers.

GNH India supplies Igantibe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company ensures quality, regulatory compliance and reliable cold‑chain logistics for biologic products throughout the supply chain.

Manufacturer / TM Owner

Instituto Grifols, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Igantibe, a human hepatitis B immunoglobulin, is used in the antiviral and hepatitis B prophylaxis therapeutic class.

  • Post‑exposure prophylaxis of hepatitis B: Provides immediate passive immunity to prevent infection after known exposure to hepatitis B virus.
  • Prevention of neonatal hepatitis B infection: Administered to newborns of HBsAg‑positive mothers to protect against perinatal transmission.
  • Protection of individuals with inadequate vaccine response: Supplies anti‑HBs antibodies to those who do not develop sufficient immunity after vaccination.

How It Works

  • Human hepatitis B immunoglobulin supplies exogenous anti‑HBs antibodies that bind to hepatitis B surface antigen, neutralizing the virus and blocking its entry into hepatocytes. The passive antibodies also facilitate viral clearance by opsonization and complement activation, thereby preventing replication and disease progression during the critical window before active immunity develops. This mechanism provides immediate protection while the host’s adaptive immune response matures.

Side Effects

Human hepatitis B immunoglobulin may be associated with injection‑site reactions and systemic responses.

Common Side Effects

  • Pain at injection site
  • Redness or swelling at injection site
  • Low‑grade fever
  • Headache
  • Fatigue
  • Nausea

Serious or Rare Side Effects

  • Anaphylactic reaction
  • Severe urticaria
  • Serum sickness‑like illness
  • Acute hemolysis
  • Thrombotic events
  • Guillain‑Barré syndrome

Precautions & Warnings

When using Igantibe, several precautions should be observed to ensure safety and product integrity.

  • Assess hepatitis B immune status: Verify HBsAg and anti‑HBs levels before administration.
  • Monitor for allergic reactions: Observe patient for signs of hypersensitivity during and after injection.
  • Use only in approved indications: Restrict use to post‑exposure prophylaxis and neonatal protection as indicated.
  • Avoid in individuals with severe IgA deficiency: Increased risk of anaphylaxis has been reported.
  • Do not mix with other injectable products: Maintain sterility and avoid incompatibility.
  • Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Igantibe can interact with certain medicines or biological agents, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid)

  • Live vaccines: Concurrent administration may diminish vaccine efficacy or increase adverse events.
  • Immunoglobulin products with different specificities: May cause immune complex formation.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: Injection site bleeding risk may be heightened; monitor coagulation parameters.
  • Corticosteroids: May mask early signs of hypersensitivity; observe closely.
  • Immunosuppressive therapy: May alter clearance of administered antibodies; adjust monitoring.

Frequently Asked Questions

Igantibe is a human hepatitis B immunoglobulin indicated for passive immunization. It is used to prevent hepatitis B virus infection after known exposure, to protect newborns of HBsAg‑positive mothers, and to provide immunity to individuals who have not responded adequately to hepatitis B vaccination.

The product supplies ready‑made anti‑HBs antibodies that bind to the hepatitis B surface antigen. This neutralizes the virus, blocks entry into liver cells, and promotes clearance through opsonization and complement activation, delivering immediate protection while the body develops its own immune response.

The dosage of Igantibe is individualized and must be prescribed by a qualified healthcare professional. The prescriber considers factors such as the patient’s age, weight, exposure risk, and hepatitis B serologic status to calculate the appropriate amount.

Data on the use of human hepatitis B immunoglobulin in pregnancy and lactation are limited. The decision to use Igantibe should be based on a careful risk‑benefit assessment by the treating physician, considering the potential benefits of preventing HBV infection for the mother and fetus.

To order Igantibe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any required import documentation.

Igantibe provides immediate passive immunity through antibodies, whereas the hepatitis B vaccine stimulates the body’s own immune system to produce protective antibodies over weeks. Igantibe is used for urgent protection after exposure or in newborns of infected mothers, while the vaccine is the primary preventive measure for long‑term immunity.

Igantibe must be stored in a refrigerated environment at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain handling is essential to maintain product potency until administration.

Igantibe is administered by a trained healthcare professional via intramuscular injection. The injection site is typically the deltoid or gluteal muscle. The exact injection technique and volume depend on the prescribed dose and patient characteristics.

Serious adverse reactions, although rare, include anaphylaxis, severe urticaria, serum‑sickness‑like illness, acute hemolysis, thrombotic events, and Guillain‑Barré syndrome. Immediate medical attention is required if any signs of a severe allergic reaction or neurological symptoms develop after injection.

Igantibe is contraindicated in individuals with a known severe allergy to human immunoglobulin preparations or any of its excipients. Patients with severe IgA deficiency should also avoid the product due to an increased risk of anaphylactic reactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Hepatitis B Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT